US-based Vyome Holdings, a clinical-stage healthcare holding company, has signed a Memorandum of Understanding (MoU) with Embryyo Technologies, India’s leading medical device innovation studio, to jointly pursue the global AI-enabled medical device market.  

The collaboration will leverage Vyome's healthcare industry experience and resources with Embryyo's medical technology capabilities to potentially productise and commercialise smart medical devices that can transform the standard of care in disease management and treatment.

"Vyome's vision is to partner with the smartest talent tackling the biggest healthcare markets along the US-India corridor and across our three pillars of pharma, AI, and medical devices. AI-enabled medical devices represent a large opportunity and the Embryyo team - helmed by Indian Institutes of Technology (IIT) alums - has been working in this sector for a decade. We will be working with them to identify the specific initiatives on which we will partner," said Krishna Gupta, Chairman of Vyome Holdings.

Nishant Kumar, Co-Founder and CEO of Embryyo Technologies, noted that the company is currently developing a portfolio of transformative medical devices spanning interventional oncology, surgery, wearables, and drug delivery.

"Vyome’s access to global capital markets and the US healthcare ecosystem will accelerate our mission to push the frontiers of medicine and elevate standards of care in healthcare globally,” he added.

As part of this partnership, Vyome and Embryyo will host a global AI-enabled medical device innovation forum for companies along the US-India corridor. The MoU is non-binding and may be subject to other conditions.